Back to User profile » Dr Josep Maria Haro
Papers published by Dr Josep Maria Haro:
Correlation of Health-Related Quality of Life in Clinically Stable Outpatients with Schizophrenia
Domenech C, Pastore A, Altamura AC, Bernasconi C, Corral R, Elkis H, Evans J, Malla A, Margari F, Krebs MO, Nordstroem AL, Zink M, Haro JM
Neuropsychiatric Disease and Treatment 2019, 15:3475-3486
Published Date: 20 December 2019
Patient-reported depression severity and cognitive symptoms as determinants of functioning in patients with major depressive disorder: a secondary analysis of the 2-year prospective PERFORM study
Haro JM, Hammer-Helmich L, Saragoussi D, Ettrup A, Larsen KG
Neuropsychiatric Disease and Treatment 2019, 15:2313-2323
Published Date: 13 August 2019
Clinical outcomes of patients with major depressive disorder treated with either duloxetine, escitalopram, fluoxetine, paroxetine, or sertraline
Huang J, Wang Y, Chen J, Zhang Y, Yuan Z, Yue L, Haro JM, Moneta MV, Novick D, Fang YR
Neuropsychiatric Disease and Treatment 2018, 14:2473-2484
Published Date: 26 September 2018
The use of random-effects models to identify health care center-related characteristics modifying the effect of antipsychotic drugs
Nordon C, Battin C, Verdoux H, Haro JM, Belger M, Abenhaim L, van Staa TP
Clinical Epidemiology 2017, 9:689-698
Published Date: 14 December 2017
Recovery in patients with major depressive disorder (MDD): results of a 6-month, multinational, observational study
Novick D, Montgomery W, Vorstenbosch E, Moneta MV, Dueñas H, Haro JM
Patient Preference and Adherence 2017, 11:1859-1868
Published Date: 31 October 2017
Comparison of clinical outcomes with orodispersible versus standard oral olanzapine tablets in nonadherent patients with schizophrenia or bipolar disorder
Novick D, Montgomery W, Treuer T, Koyanagi A, Aguado J, Kraemer S, Haro JM
Patient Preference and Adherence 2017, 11:1019-1025
Published Date: 6 June 2017
Sex differences in the course of schizophrenia across diverse regions of the world
Novick D, Montgomery W, Treuer T, Moneta MV, Haro JM
Neuropsychiatric Disease and Treatment 2016, 12:2927-2939
Published Date: 14 November 2016
Clinical features, comorbidity, and cognitive impairment in elderly bipolar patients
Rise IV, Haro JM, Gjervan B
Neuropsychiatric Disease and Treatment 2016, 12:1203-1213
Published Date: 17 May 2016
Impact of anxiety symptoms on outcomes of depression: an observational study in Asian patients
Novick D, Montgomery W, Aguado J, Peng XM, Haro JM
Neuropsychiatric Disease and Treatment 2016, 12:795-800
Published Date: 11 April 2016
Antidepressant medication treatment patterns in Asian patients with major depressive disorder
Novick D, Montgomery W, Moneta V, Peng X, Brugnoli R, Haro JM
Patient Preference and Adherence 2015, 9:421-428
Published Date: 11 March 2015
Towards Horizon 2020: challenges and advances for clinical mental health research – outcome of an expert survey
van der Feltz-Cornelis CM, van Os J, Knappe S, Schumann G, Vieta E, Wittchen HU, Lewis SW, Elfeddali I, Wahlbeck K, Linszen D, Obradors-Tarragó C, Haro JM
Neuropsychiatric Disease and Treatment 2014, 10:1057-1068
Published Date: 27 June 2014
Long-term functional improvements in the 2-year treatment of schizophrenia outpatients with olanzapine long-acting injection
Ascher-Svanum H, Novick D, Haro JM, Bertsch J, McDonnell D, Detke H
Neuropsychiatric Disease and Treatment 2014, 10:1125-1131
Published Date: 20 June 2014
Do concomitant pain symptoms in patients with major depression affect quality of life even when taking into account baseline depression severity?
Novick D, Montgomery W, Kadziola Z, Moneta V, Peng X, Brugnoli R, Haro JM
Patient Preference and Adherence 2013, 7:463-470
Published Date: 27 May 2013